Congress trades
Crinetics Pharmaceuticals, Inc. (CRNX)
About Crinetics Pharmaceuticals, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- R. Scott Struthers
- Employees
- 594
- Listed since
- Jul 18, 2018
- Market value
- $9.0B
- Price to earnings
- -
- Earnings per share
- -$4.75
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | -$1.14 | -$1.18 | $25.1M | $14.8M | EPS beatRevenue beat |
| Q1 FY2026reported May 7, 2026 | -$1.23 | -$1.22 | $10.7M | $8.5M | EPS in lineRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$1.29 | -$1.37 | $6.2M | $4.5M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$1.38 | -$1.27 | $143K | $4.3M | EPS missRevenue miss |
| Q2 FY2025reported Aug 7, 2025 | -$1.23 | -$1.13 | $1.0M | $394K | EPS missRevenue beat |
| Q1 FY2025reported May 8, 2025 | -$1.04 | -$0.99 | $361K | $348K | EPS missRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 29, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| R. Scott Struthers, Ph.D.President and Chief Executive Officer | $719K | $3.3M | $7.6M | $11.6M |
| Tobin SchilkeChief Financial Officer | $452K | $1.8M | $2.2M | $4.4M |
| Dana Pizzuti, M.D.Chief Medical and Development Officer | $573K | $1.6M | $1.8M | $3.9M |
| Stephen F. Betz, Ph.D.Chief Scientific Officer | $520K | $1.6M | $1.7M | $3.8M |
| Jeff KnightChief Operating Officer | $512K | $1.6M | $1.7M | $3.8M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $592.7M | 15,840,219 | +0.5% | 15.01% |
| Blackrock, Inc. | $365.2M | 9,758,938 | +15.1% | 9.24% |
| Farallon Capital Management LLC | $336.4M | 8,989,098 | +7.8% | 8.52% |
| Wellington Management Group LLP | $266.8M | 7,131,084 | -12.6% | 6.76% |
| Driehaus Capital Management LLC | $241.9M | 6,463,551 | +1.1% | 6.12% |
| Price T Rowe Associates Inc | $232.5M | 6,212,681 | +16.0% | 5.89% |
| Vanguard Portfolio Management LLC | $180.8M | 4,832,614 | +4.2% | 4.58% |
| Vanguard Capital Management LLC | $177.6M | 4,745,262 | +1.5% | 4.50% |
| Jupiter Topco LLC | $170.5M | 4,557,689 | +100.0% | 4.32% |
| Geode Capital Management, LLC | $102.1M | 2,727,633 | +10.0% | 2.58% |
| State Street Corp | $100.6M | 2,689,350 | +11.9% | 2.55% |
| Bellevue Group AG | $98.0M | 2,620,000 | -20.1% | 2.48% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in CRNX
6 disclosures of 6 on record · median 22d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $15,001 - $50,000 | +1.6%S&P +3.4% · vs S&P 500 -1.8% | Jul 30, 2026 | Sep 4, 2026 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +111.7%S&P +12.7% · vs S&P 500 +99.1% | Mar 3, 2026 | Apr 7, 2026 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +179.3%S&P +45.7% · vs S&P 500 +133.6% | Apr 17, 2025 | May 6, 2025 | 19d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +145.0%S&P +35.2% · vs S&P 500 +109.8% | Mar 19, 2025 | Apr 10, 2025 | 22d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +115.7%S&P +27.4% · vs S&P 500 +88.4% | Jan 29, 2025 | Feb 11, 2025 | 13d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +68.4%S&P +34.1% · vs S&P 500 +34.3% | Sep 25, 2024 | Oct 3, 2024 | 8d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 7, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded CRNX?
Gilbert Ray Cisneros, Jr., Josh Gottheimer disclosed CRNX transactions in the filings shown here.
How quickly are CRNX trades disclosed?
Congressional disclosures took a median of 22 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.